These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 11802256)
1. Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers. Tan KH; Hyman-Tylor P; Mulheran M; Knox A; Smyth A Pediatr Pulmonol; 2002 Feb; 33(2):165. PubMed ID: 11802256 [No Abstract] [Full Text] [Related]
2. Tobramycin dosing in cystic fibrosis. Smyth A; Touw D; Tan KH; Bertenshaw C; Stableforth D Lancet; 2005 May 21-27; 365(9473):1767-8. PubMed ID: 15910946 [No Abstract] [Full Text] [Related]
3. Tobramycin inhalation solution (Bethkis) for cystic fibrosis. Med Lett Drugs Ther; 2014 Jun; 56(1445):51-2. PubMed ID: 24956309 [No Abstract] [Full Text] [Related]
4. Minimizing the toxicity of aminoglycosides in cystic fibrosis. Smyth AR J R Soc Med; 2010 Jul; 103 Suppl 1(Suppl 1):S3-5. PubMed ID: 20573667 [No Abstract] [Full Text] [Related]
5. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482 [TBL] [Abstract][Full Text] [Related]
6. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs? Vandenbussche HL; Klepser ME Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080 [No Abstract] [Full Text] [Related]
7. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis. Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061 [No Abstract] [Full Text] [Related]
8. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis. Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798 [No Abstract] [Full Text] [Related]
9. Unwarranted use of intravenous aminoglycosides at UK paediatric cystic fibrosis centres. Ditchfield N; Carroll WD; Gilchrist FJ J Cyst Fibros; 2019 Nov; 18(6):e58-e59. PubMed ID: 31522925 [No Abstract] [Full Text] [Related]
10. [Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection]. Mordasini C; Aebischer CC; Schoch OD Schweiz Med Wochenschr; 1997 May; 127(21):905-10. PubMed ID: 9289818 [TBL] [Abstract][Full Text] [Related]
11. Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis. Akbar A; Rees JH; Nyamugunduru G; English MW; Spencer DA; Weller PH Acta Paediatr; 1999 Jul; 88(7):783-5. PubMed ID: 10447142 [TBL] [Abstract][Full Text] [Related]
12. Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis. Nikolaizik WH; Jenni-Galović V; Schöni MH Eur J Pediatr; 1996 Jul; 155(7):608-11. PubMed ID: 8831087 [TBL] [Abstract][Full Text] [Related]
13. NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosis. Nolan K; Knight H; Clark P Lancet Respir Med; 2013 Apr; 1(2):102-3. PubMed ID: 24429083 [No Abstract] [Full Text] [Related]
14. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial. Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A; Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100 [TBL] [Abstract][Full Text] [Related]
15. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence. Hamed K; Debonnett L Ther Adv Respir Dis; 2017 May; 11(5):193-209. PubMed ID: 28470103 [TBL] [Abstract][Full Text] [Related]